Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spine Asia CoROCO:6758 +0.67%80 EV-to-EBIT is 33.16 as of Sep. 13, 2026, which is 21% above its 10-year median of 27.47. GuruFocus rates ROCO:6758 with a GF Score™ of 80/100 and a GF Value™ of NT$44.72 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Spine Asia Co ranks worse than 75.53% on this metric.
The historical rank and industry rank for Spine Asia Co's EV-to-EBIT or its related term are showing as below:
ROCO:6758'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.48 Med: 27.47 Max: 53.03
Current: 33.16
During the past 10 years, the highest EV-to-EBIT of Spine Asia Co was 53.03. The lowest was 11.48. And the median was 27.47.
ROCO:6758's EV-to-EBIT is ranked worse than 75.53% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 18.005
vs ROCO:6758: 33.16
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Spine Asia Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$502.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spine Asia Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$15.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spine Asia Co EV-to-EBIT Related Terms
Spine Asia Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Spine Asia Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Spine Asia Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spine Asia Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Spine Asia Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Spine Asia Co's EV-to-EBIT falls into.
Spine Asia Co's current Enterprise Value is NT$502.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spine Asia Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$15.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spine Asia Co (ROCO:6758) has a EV-to-EBIT of 33.16 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spine Asia Co and its competitors. This is 21% above median its historical median of 27.47. Over the past decade, Spine Asia Co's EV-to-EBIT has ranged from 11.48 to 53.03. According to the industry distribution chart, Spine Asia Co ranks #358 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 75.5%.
Is Spine Asia Co's EV-to-EBIT too high?
Spine Asia Co's current EV-to-EBIT of 33.16 is 21% above median its 10-year median of 27.47. Over the past 10 years, this metric has ranged from a low of 11.48 to a high of 53.03. The Medical Devices & Instruments industry median EV-to-EBIT is 18.01. Spine Asia Co's value of 33.16 is 84.2% above this industry median. Based on the distribution chart, Spine Asia Co ranks #358 out of 474 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Spine Asia Co has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Spine Asia Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Spine Asia Co ranks #358 out of 474 companies for EV-to-EBIT. This places Spine Asia Co in the lower half of its industry. The industry median EV-to-EBIT is 18.01. Spine Asia Co's value of 33.16 is 84.2% above this benchmark. Historically, Spine Asia Co's own EV-to-EBIT has ranged from 11.48 to 53.03 over the past decade. While the company's 10-year median is 27.47 vs. the industry median of 18.01, Spine Asia Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.01, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spine Asia Co's current EV-to-EBIT of 33.16 is 84.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spine Asia Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spine Asia Co's current EV-to-EBIT is 33.16, which is 21% above median its own 10-year median of 27.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spine Asia Co stock overvalued right now?
Based on GuruFocus' analysis, Spine Asia Co (ROCO:6758) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$44.72, compared to a current price of NT$30.00 — trading 32.9% below its estimated fair value. The current EV-to-EBIT is 33.16, which is 21% above median its 10-year median of 27.47 and 84.2% above the Medical Devices & Instruments industry median of 18.01. Spine Asia Co's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Spine Asia Co (ROCO:6758), the current EV-to-EBIT is 33.16 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spine Asia Co (ROCO:6758) Overvalued in 2026?
Based on GuruFocus' analysis, Spine Asia Co stock appears to be undervalued.
The current stock price of NT$30.00 is trading 32.9% below its estimated GF Value™ of NT$44.72.
GuruFocus considers Spine Asia Co to be Significantly Undervalued.
Key valuation signals for ROCO:6758:
EV-to-EBIT: 33.16 (21% above median its 10-year median of 27.47)
GF Value™: NT$44.72 vs. price of NT$30.00 (32.9% below fair value)
Industry Position: 84.2% above the Medical Devices & Instruments median (#358 of 474)
No single metric tells the full story. See the ROCO:6758 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spine Asia Co Ltd is a medical device company. It is engaged in the research, development, manufacturing, and marketing of spinal, implants and instruments. The company offers products such as vigor lumbar peek cage, remond polymer cervical cage, and combo cervical disc cage.
80GF Score
Get the complete analysis for ROCO:6758
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6758 has been successfully added to your 
